Humanity
#BenevolentAI #midjourney #aiart #midjourneyai #midjourneyart #ai #art #aiartcommunity #aigenerated
#digitalart
#BenevolentAI #midjourney #aiart #midjourneyai #midjourneyart #ai #art #aiartcommunity #aigenerated
#digitalart
November 23, 2024 at 6:00 AM
#Dualrealitieschallenge26
The Guardian's Choice
What if the most powerful intelligence ever created chose compassion over conquest?
#HeroicUltron #BenevolentAI #SciFiArt #FutureHumanity #AIart #AIchallenge #aiartcommunity #aiartist #GenAI #GenerativeArt #SynthArt #BuilderofNightmares
The Guardian's Choice
What if the most powerful intelligence ever created chose compassion over conquest?
#HeroicUltron #BenevolentAI #SciFiArt #FutureHumanity #AIart #AIchallenge #aiartcommunity #aiartist #GenAI #GenerativeArt #SynthArt #BuilderofNightmares
August 7, 2026 at 12:49 AM
#Dualrealitieschallenge26
The Guardian's Choice
What if the most powerful intelligence ever created chose compassion over conquest?
#HeroicUltron #BenevolentAI #SciFiArt #FutureHumanity #AIart #AIchallenge #aiartcommunity #aiartist #GenAI #GenerativeArt #SynthArt #BuilderofNightmares
The Guardian's Choice
What if the most powerful intelligence ever created chose compassion over conquest?
#HeroicUltron #BenevolentAI #SciFiArt #FutureHumanity #AIart #AIchallenge #aiartcommunity #aiartist #GenAI #GenerativeArt #SynthArt #BuilderofNightmares
I interviewed with BenevolentAI. Absolutely dodged a bullet there. And I knew the sex pest former ceo of ExScentia. Never found out why he'd left GSK in such a hurry. But it was an HR issue apparently. I knew him after this.
September 10, 2025 at 7:16 AM
I interviewed with BenevolentAI. Absolutely dodged a bullet there. And I knew the sex pest former ceo of ExScentia. Never found out why he'd left GSK in such a hurry. But it was an HR issue apparently. I knew him after this.
I’ve heard about BenevolentAI but haven’t checked out their work.
@recursionpharma.bsky.social been making leaps recently, definitely keep an eye out
@recursionpharma.bsky.social been making leaps recently, definitely keep an eye out
November 24, 2024 at 6:35 PM
I’ve heard about BenevolentAI but haven’t checked out their work.
@recursionpharma.bsky.social been making leaps recently, definitely keep an eye out
@recursionpharma.bsky.social been making leaps recently, definitely keep an eye out
DeepMind spinout Isomorphic Labs has poached a significant chunk of its headcount from rivals Exscientia and BenevolentAI, after they struggled to retain a foothold in a challenging drug discovery market.
sifted.eu/articles/iso...
sifted.eu/articles/iso...
DeepMind spinout Isomorphic Labs poaches talent from embattled AI rivals
The Demis Hassabis-founded company raised a $600m round from Thrive Capital on Monday
sifted.eu
April 1, 2025 at 8:37 AM
DeepMind spinout Isomorphic Labs has poached a significant chunk of its headcount from rivals Exscientia and BenevolentAI, after they struggled to retain a foothold in a challenging drug discovery market.
sifted.eu/articles/iso...
sifted.eu/articles/iso...
In this month's ChemDev poster by Augustin "Gus" Péneau, we explore the process development behind a campaign to establish a manufacturing route for a topical pan-Trk inhibitor by Neil Stevenson with the BenevolentAI team!
Key paper: doi.org/10.1021/acs....
Key paper: doi.org/10.1021/acs....
June 6, 2026 at 7:26 PM
In this month's ChemDev poster by Augustin "Gus" Péneau, we explore the process development behind a campaign to establish a manufacturing route for a topical pan-Trk inhibitor by Neil Stevenson with the BenevolentAI team!
Key paper: doi.org/10.1021/acs....
Key paper: doi.org/10.1021/acs....
In #SmallMol and #Biologics #Antibodies and #BigPharma, Bristol-Myers Squibb $BMY, Novo Nordisk $NVO, $VRTX Vertex, Abbvie $ABBV, Regeneron $REGN, Sanofi, Recursion $RXRX, BenevolentAI, Exscientia (now part of Recursion Pharma), AbSci $ABSI, AbCam (now part of Danaher $DHR), AbCellera $ABCL
February 10, 2025 at 10:12 AM
In #SmallMol and #Biologics #Antibodies and #BigPharma, Bristol-Myers Squibb $BMY, Novo Nordisk $NVO, $VRTX Vertex, Abbvie $ABBV, Regeneron $REGN, Sanofi, Recursion $RXRX, BenevolentAI, Exscientia (now part of Recursion Pharma), AbSci $ABSI, AbCam (now part of Danaher $DHR), AbCellera $ABCL
⭐ Hear from Dr Peter Cox from Isomorphic Labs at our online event exploring AI across drug discovery on 14 Jan 2026 ⭐
Peter has over 25 years in the pharmaceutical industry, leading projects from Pfizer to BenevolentAI.
📅 14 January 26
💻 Online
👉 Register
my.bps.ac.uk/events/detai...
Peter has over 25 years in the pharmaceutical industry, leading projects from Pfizer to BenevolentAI.
📅 14 January 26
💻 Online
👉 Register
my.bps.ac.uk/events/detai...
November 18, 2025 at 1:16 PM
⭐ Hear from Dr Peter Cox from Isomorphic Labs at our online event exploring AI across drug discovery on 14 Jan 2026 ⭐
Peter has over 25 years in the pharmaceutical industry, leading projects from Pfizer to BenevolentAI.
📅 14 January 26
💻 Online
👉 Register
my.bps.ac.uk/events/detai...
Peter has over 25 years in the pharmaceutical industry, leading projects from Pfizer to BenevolentAI.
📅 14 January 26
💻 Online
👉 Register
my.bps.ac.uk/events/detai...
7/ Example:
Verge Genomics’ AI-discovered drug VRG50635 entered clinical trials, and Phase 1 results were positive.
But it’s early days — the real test is whether it meets endpoints in later phases.
BenevolentAI recently had layoffs after a Phase 2 failure. AI isn’t magic.
Verge Genomics’ AI-discovered drug VRG50635 entered clinical trials, and Phase 1 results were positive.
But it’s early days — the real test is whether it meets endpoints in later phases.
BenevolentAI recently had layoffs after a Phase 2 failure. AI isn’t magic.
January 7, 2025 at 2:15 PM
7/ Example:
Verge Genomics’ AI-discovered drug VRG50635 entered clinical trials, and Phase 1 results were positive.
But it’s early days — the real test is whether it meets endpoints in later phases.
BenevolentAI recently had layoffs after a Phase 2 failure. AI isn’t magic.
Verge Genomics’ AI-discovered drug VRG50635 entered clinical trials, and Phase 1 results were positive.
But it’s early days — the real test is whether it meets endpoints in later phases.
BenevolentAI recently had layoffs after a Phase 2 failure. AI isn’t magic.
🤖💊 The AI Drug Discovery Market is revolutionizing pharma with machine learning & big data.
Key players:
🔹 @BenevolentAI
🔹 @Atomwise
🔹 @InsilicoMed
#AIDrugDiscovery #PharmaInnovation #AIHealth #MRFR
www.marketresearchfuture.com/reports/ai-d...
Key players:
🔹 @BenevolentAI
🔹 @Atomwise
🔹 @InsilicoMed
#AIDrugDiscovery #PharmaInnovation #AIHealth #MRFR
www.marketresearchfuture.com/reports/ai-d...
Artificial Intelligence (AI) in Drug Discovery Market 2035
Artificial Intelligence (AI) in Drug Discovery Market projected to grow at 17.11% CAGR, reaching USD 25 Billion by 2035, driving growth global trends, competitive industry analysis and outlook 2025-20...
www.marketresearchfuture.com
October 6, 2025 at 9:32 AM
🤖💊 The AI Drug Discovery Market is revolutionizing pharma with machine learning & big data.
Key players:
🔹 @BenevolentAI
🔹 @Atomwise
🔹 @InsilicoMed
#AIDrugDiscovery #PharmaInnovation #AIHealth #MRFR
www.marketresearchfuture.com/reports/ai-d...
Key players:
🔹 @BenevolentAI
🔹 @Atomwise
🔹 @InsilicoMed
#AIDrugDiscovery #PharmaInnovation #AIHealth #MRFR
www.marketresearchfuture.com/reports/ai-d...
Seems we are starting to hit this phase of AI.
Here is a talk I did about AI in medicine 7 years ago. And the concept of over ruling an AI decision support system:
youtu.be/LCTW3IoX5jQ?...
It would be interest to have a large scale study to understand the level of false positives here too.
Here is a talk I did about AI in medicine 7 years ago. And the concept of over ruling an AI decision support system:
youtu.be/LCTW3IoX5jQ?...
It would be interest to have a large scale study to understand the level of false positives here too.
#BIOAI2017 Navin Ramachandran, UCLH: Issues to consider in adopting AI?
YouTube video by BenevolentAI
youtu.be
November 18, 2024 at 9:22 PM
Seems we are starting to hit this phase of AI.
Here is a talk I did about AI in medicine 7 years ago. And the concept of over ruling an AI decision support system:
youtu.be/LCTW3IoX5jQ?...
It would be interest to have a large scale study to understand the level of false positives here too.
Here is a talk I did about AI in medicine 7 years ago. And the concept of over ruling an AI decision support system:
youtu.be/LCTW3IoX5jQ?...
It would be interest to have a large scale study to understand the level of false positives here too.
www3.nhk.or.jp/nhkworld/en/...
Very happy to raise awareness of the needs of >1bn people affected by terrible neglected diseases such as #Dengue and to highlight the exciting work we have been doing with our colleagues at #BenevolentAI.
Dengue item is at minutes 9:00-12:30 in AI story from 7:30
Very happy to raise awareness of the needs of >1bn people affected by terrible neglected diseases such as #Dengue and to highlight the exciting work we have been doing with our colleagues at #BenevolentAI.
Dengue item is at minutes 9:00-12:30 in AI story from 7:30
Riding High on New Wave of Renewable Energy Tech - BIZ STREAM | NHK WORLD-JAPAN
[On-Site Report: Riding High on New Wave of Renewable Energy Tech] This episode focuses on advances in renewable energy and features a massive lightweight hard sail designed for cargo ships and an ult...
www3.nhk.or.jp
January 20, 2025 at 10:19 AM
www3.nhk.or.jp/nhkworld/en/...
Very happy to raise awareness of the needs of >1bn people affected by terrible neglected diseases such as #Dengue and to highlight the exciting work we have been doing with our colleagues at #BenevolentAI.
Dengue item is at minutes 9:00-12:30 in AI story from 7:30
Very happy to raise awareness of the needs of >1bn people affected by terrible neglected diseases such as #Dengue and to highlight the exciting work we have been doing with our colleagues at #BenevolentAI.
Dengue item is at minutes 9:00-12:30 in AI story from 7:30
Bear with me here. But I did a talk on this 6 years ago or so of how this could play out in medicine. And there are a lot of parallels with Naomi’s article.
Things have moved much quicker than I expected unfortunately…
https://youtu.be/LCTW3IoX5jQ
Things have moved much quicker than I expected unfortunately…
https://youtu.be/LCTW3IoX5jQ
#BIOAI2017 Navin Ramachandran, UCLH: Issues to consider in adopting AI?
If you are interested to hear more about the advancements of Artificial Intelligence in Bioscience, join Special Interest Group on Artificial Intelligence in Biomedicine http://benevolent.ai/blog/benevolentai/join-the-special-interest-group-on-artificial-intelligence-in-biomedicine/
Navin Ramachandran, UCLH, Peach Lab: When considering the role of any technology in society, we must consider the potential for harm. This talk will examine the different ways in which harm may manifest, as a result of currently established and newly emerging techniques in artificial intelligence
youtu.be
May 10, 2023 at 7:30 AM
Bear with me here. But I did a talk on this 6 years ago or so of how this could play out in medicine. And there are a lot of parallels with Naomi’s article.
Things have moved much quicker than I expected unfortunately…
https://youtu.be/LCTW3IoX5jQ
Things have moved much quicker than I expected unfortunately…
https://youtu.be/LCTW3IoX5jQ
So AI is not magic, and it is not a hammer wandering around looking for nails.
Find the problem first. Then decide if AI is the right tool, or if a brick gets it done.
My full take, three years in: divingintogeneticsandgenomics.com/post/has-ai...
Find the problem first. Then decide if AI is the right tool, or if a brick gets it done.
My full take, three years in: divingintogeneticsandgenomics.com/post/has-ai...
Has AI Changed the Course of Drug Development? Three Years Later
A bioinformatics director's honest take on AI in drug development, three years after the original post. Updates on Recursion, BenevolentAI, Verge Genomics, plus what's actually working in the clinic and where the field is still stuck.
divingintogeneticsandgenomics.com
August 7, 2026 at 1:45 PM
So AI is not magic, and it is not a hammer wandering around looking for nails.
Find the problem first. Then decide if AI is the right tool, or if a brick gets it done.
My full take, three years in: divingintogeneticsandgenomics.com/post/has-ai...
Find the problem first. Then decide if AI is the right tool, or if a brick gets it done.
My full take, three years in: divingintogeneticsandgenomics.com/post/has-ai...
🔥 GSK Bets £50M on BenevolentAI to Cut Drug Discovery Timelines by 30%
#24hHotNewsAI #GBNews
#24hHotNewsAI #GBNews
GSK Bets £50M on BenevolentAI to Cut Drug Discovery Timelines by 30%
GSK invests £50M in BenevolentAI to cut drug discovery timelines by 30% using AI predictive modeling. The partnership leverages BenevolentAI's Knowledge Graph to analyze vast biomedical data, accelerating candidate identification.
24hhotnewsai.com
July 30, 2026 at 7:16 AM
🔥 GSK Bets £50M on BenevolentAI to Cut Drug Discovery Timelines by 30%
#24hHotNewsAI #GBNews
#24hHotNewsAI #GBNews
Hantavirus Has No Antiviral. The AI Drug Discovery Companies Most Likely to Build One
https://www.startuphub.ai/ai-news/ai/2026/ai-drug-discovery-hantavirus-antiviral-gap-2026
https://www.startuphub.ai/ai-news/ai/2026/ai-drug-discovery-hantavirus-antiviral-gap-2026
Hantavirus Has No Antiviral. The AI Drug Discovery Companies Most Likely to Build One
The Andes-virus cluster aboard the MV Hondius killed three people and reminded the world that hantavirus has no licensed antiviral. The AI drug-discovery companies most likely to change that -- Isomorphic Labs, Insilico Medicine, Insitro, Recursion, Exscientia, Absci, BenevolentAI, and Owkin -- are
www.startuphub.ai
May 12, 2026 at 1:55 PM
Hantavirus Has No Antiviral. The AI Drug Discovery Companies Most Likely to Build One
https://www.startuphub.ai/ai-news/ai/2026/ai-drug-discovery-hantavirus-antiviral-gap-2026
https://www.startuphub.ai/ai-news/ai/2026/ai-drug-discovery-hantavirus-antiviral-gap-2026
"AI Copyright Consultation" with Sonia Cooper, Microsoft, Antonio Weiss, The PSC, Kir Nuthi, Startup Coalition, Kevin Zandermann, Tony Blair Institute for Global Change, Will Scrimshaw, BenevolentAI, Ben White, KR21. Watch the full video from SOOCon25: buff.ly/4ht27b3
April 29, 2025 at 1:05 PM
"AI Copyright Consultation" with Sonia Cooper, Microsoft, Antonio Weiss, The PSC, Kir Nuthi, Startup Coalition, Kevin Zandermann, Tony Blair Institute for Global Change, Will Scrimshaw, BenevolentAI, Ben White, KR21. Watch the full video from SOOCon25: buff.ly/4ht27b3
Feed: "Business-News-Today.com"
By: Soujanya Ravi on Thursday, September 18, 2025
By: Soujanya Ravi on Thursday, September 18, 2025
Formation Bio hires ex-Pfizer and BenevolentAI leaders to supercharge its AI-driven drug development model
Formation Bio bolsters its leadership team with top biotech and pharma veterans to fast-track its AI-driven drug development model.
business-news-today.com
September 18, 2025 at 10:17 PM
Feed: "Business-News-Today.com"
By: Soujanya Ravi on Thursday, September 18, 2025
By: Soujanya Ravi on Thursday, September 18, 2025
Feed: "ABNewswire"
By: admin on Monday, September 8, 2025
By: admin on Monday, September 8, 2025
Amyotrophic Lateral Sclerosis Pipeline 2025: FDA Approvals and Clinical Trials Landscape with MOA and ROA Highlights by DelveInsight | COSCIENS Biopharma, BenevolentAI, Verge Genomics, ProJenX
(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Amyotrophic Lateral Sclerosis pipeline constitutes 70+ key companies continuously working towards developing 80+ Amyotrophic Lateral Sclerosis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and … Continue reading →
www.abnewswire.com
September 8, 2025 at 6:51 PM
Feed: "ABNewswire"
By: admin on Monday, September 8, 2025
By: admin on Monday, September 8, 2025
And yet they do. Weird.
www.techuk.org/resource/aiw...
BenevolentAI also uses large language models (LLM) to identify biological targets.
They use other forms of AI, too.
www.techuk.org/resource/aiw...
BenevolentAI also uses large language models (LLM) to identify biological targets.
They use other forms of AI, too.
The Benevolent PlatformTM augments scientific ingenuity with AI to navigate an ever-expanding data landscape to map complex diseases (Guest blog by BenevolentAI)
Guest blog by Laura Taddei, Director of Business Affairs at BenevolentAI
www.techuk.org
December 25, 2024 at 11:31 PM
And yet they do. Weird.
www.techuk.org/resource/aiw...
BenevolentAI also uses large language models (LLM) to identify biological targets.
They use other forms of AI, too.
www.techuk.org/resource/aiw...
BenevolentAI also uses large language models (LLM) to identify biological targets.
They use other forms of AI, too.
BenevolentAI, Exscientia on the comeback trail after securing separate AI drug discovery deals with Merck KGaA
https://endpts.com/benevolentai-exscientia-on-the-comeback-trail-after-securing-separate-ai-drug-discovery-deals-with-merck-kgaa/
https://endpts.com/benevolentai-exscientia-on-the-comeback-trail-after-securing-separate-ai-drug-discovery-deals-with-merck-kgaa/
September 20, 2023 at 4:51 PM
BenevolentAI, Exscientia on the comeback trail after securing separate AI drug discovery deals with Merck KGaA
https://endpts.com/benevolentai-exscientia-on-the-comeback-trail-after-securing-separate-ai-drug-discovery-deals-with-merck-kgaa/
https://endpts.com/benevolentai-exscientia-on-the-comeback-trail-after-securing-separate-ai-drug-discovery-deals-with-merck-kgaa/
Is the AI-driven drug discovery sliding down the hype curve?
As reflected in stock prices, the public is losing confidence. Now, BenevolentAI, once a flagship of AI-first drug discovery, appears to be pivoting from full-scale drug discovery to services.
www.businesswire.com/news/home/20...
As reflected in stock prices, the public is losing confidence. Now, BenevolentAI, once a flagship of AI-first drug discovery, appears to be pivoting from full-scale drug discovery to services.
www.businesswire.com/news/home/20...
December 12, 2024 at 5:59 AM
Is the AI-driven drug discovery sliding down the hype curve?
As reflected in stock prices, the public is losing confidence. Now, BenevolentAI, once a flagship of AI-first drug discovery, appears to be pivoting from full-scale drug discovery to services.
www.businesswire.com/news/home/20...
As reflected in stock prices, the public is losing confidence. Now, BenevolentAI, once a flagship of AI-first drug discovery, appears to be pivoting from full-scale drug discovery to services.
www.businesswire.com/news/home/20...